Novel Strategy to Prevent Atrial Fibrosis and Fibrillation

Circulation Journal

Volumn 76, Issue 10, 2012, Pages 2318-2326

  Takahashi, Naohiko ^a   Kume, Osamu ^a   Wakisaka, Osamu ^a   Fukunaga, Naoya ^a   Teshima, Yasushi ^a   Hara, Masahide ^a   Saikawa, Tetsunori ^a  

^a OITA UNIVERSITY   (Japan)

Author keywords

Atrial fibrillation; Fibrosis; Inflammation

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; ANGIOTENSIN II; ANTIOXIDANT; ATRIAL NATRIURETIC FACTOR; COLLAGEN TYPE 1; GELATINASE B; GLYCERALDEHYDE 3 PHOSPHATE DEHYDROGENASE; HEAT SHOCK PROTEIN 72; MALONALDEHYDE; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MONOCYTE CHEMOTACTIC PROTEIN 1; PIOGLITAZONE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE; TEPRENONE; TRANSFORMING GROWTH FACTOR BETA1;

ARTICLE; CHRONIC KIDNEY DISEASE; DISEASE ASSOCIATION; ENDOCARDIUM; ENDOTHELIUM CELL; HEART ATRIUM CONDUCTION; HEART ATRIUM ENLARGEMENT; HEART ATRIUM FIBRILLATION; HEART LEFT VENTRICLE OVERLOAD; HEART MUSCLE FIBROSIS; HEART MUSCLE REFRACTORY PERIOD; HEART PROTECTION; HUMAN; HYPERTHERMIA; NEPHRECTOMY; NONHUMAN; OXIDATIVE STRESS; P WAVE; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; SINUS RHYTHM; WESTERN BLOTTING;

ANIMALS; ANTIOXIDANTS; ATRIAL FIBRILLATION; CHEMOKINE CCL2; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; FIBROSIS; GENE EXPRESSION REGULATION; HSP72 HEAT-SHOCK PROTEINS; HUMANS; HYPOGLYCEMIC AGENTS; HYPOTHERMIA; PPAR GAMMA; THIAZOLIDINEDIONES;

EID: 84867866482     PISSN: 13469843     EISSN: 13474820     Source Type: Journal    
DOI: 10.1253/circj.CJ-12-1099     Document Type: Article

References (57)

1. Burstein B, Nattel S. Atrial fibrosis: Mechanisms and clinical relevance in atrial fibrillation. J Am Coll Cardiol 2008; 51: 802-809.
2. Kumagai K, Nakashima H, Urata H, Gondo N, Arakawa K, Saku K. Effects of angiotensin II type 1 receptor antagonist on electrical and structural remodeling in atrial fibrillation. J Am Coll Cardiol 2003; 41: 2197-2204.
3. Nakashima H, Kumagai K, Urata H, Gondo N, Ideishi M, Arakawa K. Angiotensin II antagonist prevents electrical remodeling in atrial fibrillation. Circulation 2000; 101: 2612-2617.
4. Kumagai K, Nakashima H, Saku K. The HMG-CoA reductase inhibitor atorvastatin prevents atrial fibrillation by inhibiting inflammation in a canine sterile pericarditis model. Cardiovasc Res 2004; 62: 105-111.
5. Sakabe M, Shiroshita-Takeshita A, Maguy A, Dumesnil C, Nigam A, Leung TK, et al. Omega-3 polyunsaturated fatty acids prevent atrial fibrillation associated with heart failure but not atrial tachycardia remodeling. Circulation 2007; 116: 2101-2109.
6. GISSI-AF Investigators, Disertori M, Latini R, Barlera S, Franzosi MG, Staszewsky L, Maggioni AP, et al. Valsartan for prevention of recurrent atrial fibrillation. N Engl J Med 2009; 360: 1606-1617.
7. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology guidelines. Part I: Primary prevention. Europace 2011; 13: 308-328.
8. Savelieva I, Kakouros N, Kourliouros A, Camm AJ. Upstream therapies for management of atrial fibrillation: Review of clinical evidence and implications for European Society of Cardiology guidelines. Part II: Secondary prevention. Europace 2011; 13: 610-625.
9. Iwasaki YK, Nishida K, Kato T, Nattel S. Atrial fibrillation pathophysiology: Implications for management. Circulation 2011; 124: 2264-2274.
10. Takahashi N, Kume O, Wakisaka O, Teshima Y, Hara M, Saikawa T. New therapeutic target for the non-electrophysiological signaling in atrial fibrosis and fibrillation such as inflammation. J Arrhythmias 2012; 28: 145-154.
11. Wijffels MC, Kirchhof CJ, Dorland R, Allessie MA. Atrial fibrillation begets atrial fibrillation: study in awake chronically instrumented goats. Circulation 1995; 92: 1954-1968.
12. Kume O, Takahashi N, Wakisaka O, Nagano-Torigoe Y, Teshima Y, Nakagawa M, et al. Pioglitazone attenuates inflammatory atrial fibrosis and vulnerability to atrial fibrillation induced by pressure overload in rats. Heart Rhythm 2011; 8: 278-285.
13. Wakisaka O, Takahashi N, Shinohara T, Ooie T, Nakagawa M, Yonemochi H, et al. Hyperthermia treatment prevents angiotensin II-mediated atrial fibrosis and fibrillation via induction of heat-shock protein 72. J Mol Cell Cardiol 2007; 43: 616-626.
14. Fukunaga N, Takahashi N, Hagiwara S, Kume O, Fukui A, Teshima Y, et al. Establishment of a model of atrial fibrillation associated with chronic kidney disease in rats and the role of oxidative stress. Heart Rhythm 2012 August 17 [Epub ahead of print].
15. Kai H, Kuwahara F, Tokuda K, Imaizumi T. Diastolic dysfunction in hypertensive hearts: Roles of perivascular inflammation and reactive myocardial fibrosis. Hypertens Res 2005; 28: 483-490.
16. Zhang C, Yasuno S, Kuwahara K, Zankov DP, Kobori A, Makiyama T, et al. Blockade of angiotensin II type 1 receptor improves the arrhythmia morbidity in mice with left ventricular hypertrophy. Circ J 2006; 70: 335-341.
17. Adam O, Frost G, Custodis F, Sussman MA, Schäfers HJ, Böhm M, et al. Role of rac1 GTPase activation in atrial fibrillation. J Am Coll Cardiol 2007; 50: 359-367.
18. Ceriello A. Thiazolidinediones as anti-inflammatory and anti-atherogenic agents. Diabetes Metab Res Rev 2008; 24: 14-26.
19. Nakamoto M, Ohya Y, Shinzato T, Mano R, Yamazato M, Sakima A, et al. Pioglitazone, a thiazolidinedione derivative, attenuates left ventricular hypertrophy and fibrosis in salt-sensitive hypertension. Hypertens Res 2008; 31: 353-361.
20. Kato MF, Shibata R, Obata K, Miyachi M, Yazawa H, Tsuboi K, et al. Pioglitazone attenuates cardiac hypertrophy in rats with salt-sensitive hypertension: Role of activation of AMP-activated protein kinase and inhibition of Akt. J Hypertens 2008; 26: 1669-1676.
21. Shimano M, Tsuji Y, Inden Y, Kitamura K, Uchikawa T, Harata S, et al. Pioglitazone, a peroxisome proliferator-activated receptor-gamma activator, attenuates atrial fibrosis and atrial fibrillation promotion in rabbits with congestive heart failure. Heart Rhythm 2008; 5: 451-459.
22. Xu D, Murakoshi N, Igarashi M, Hirayama A, Ito Y, Seo Y, et al. PPAR-γ activator pioglitazone prevents age-related atrial fibrillation susceptibility by improving antioxidant capacity and reducing apoptosis in a rat model. J Cardiovasc Electrophysiol 2012; 23: 209-217.
23. Gu J, Liu X, Wang X, Shi H, Tan H, Zhou L, et al. Beneficial effect of pioglitazone on the outcome of catheter ablation in patients with paroxysmal atrial fibrillation and type 2 diabetes mellitus. Europace 2011; 13: 1256-1261.
24. Manabe I. Chronic inflammation links cardiovascular, metabolic and renal diseases. Circ J 2011; 75: 2739-2748.
25. Yamashita T, Sekiguchi A, Iwasaki YK, Date T, Sagara K, Tanabe H, et al. Recruitment of immune cells across atrial endocardium in human atrial fibrillation. Circ J 2010; 74: 262-270.
26. Ooie T, Takahashi N, Saikawa T, Nawata T, Arikawa M, Yamanaka K, et al. Single oral dose of geranylgeranylacetone induces heat-shock protein 72 and renders protection against ischemia/reperfusion injury in rat heart. Circulation 2001; 104: 1837-1843.
27. Benjamin IJ, McMillan DR. Stress (heat shock) proteins: Molecular chaperones in cardiovascular biology and disease. Circ Res 1998; 83: 117-132.
28. Vricella LA, Dearani JA, Gundry SR, Razzouk AJ, Brauer SD, Bailey LL. Association of high intracellular, but not serum, heat shock protein 70 with postoperative atrial fibrillation. Ann Thorac Surg 2005; 79: 865-871.
29. Brundel BJ, Henning RH, Ke L, van Gelder IC, Crijns HJ, Kampinga HH. Heat shock protein upregulation protects against pacing-induced myolysis in HL-1 atrial myocytes and in human atrial fibrillation. J Mol Cell Cardiol 2006; 41: 555-562.
30. Brundel BJ, Shiroshita-Takeshita A, Qi X, Yeh YH, Chartier D, van Gelder IC, et al. Induction of heat shock response protects the heart against atrial fibrillation. Circ Res 2006; 99: 1394-1402.
31. Krahn AD, Manfreda J, Tate RB, Mathewson FA, Cuddy TE. The natural history of atrial fibrillation: Incidence, risk factors, and prognosis in the Manitoba follow-up study. Am J Med 1995; 98: 476-484.
32. Sinno H, Derakhchan K, Libersan D, Merhi Y, Leung TK, Nattel S. Atrial ischemia promotes atrial fibrillation in dogs. Circulation 2003; 107: 1930-1936.
33. Sakabe M, Shiroshita-Takeshita A, Maguy A, Brundel BJ, Fujiki A, Inoue H, et al. Effects of a heat shock protein inducer on the atrial fibrillation substrate caused by acute atrial ischaemia. Cardiovasc Res 2008; 78: 63-70.
34. Yamanaka K, Takahashi N, Ooie T, Kaneda K, Yoshimatsu H, Saikawa T. Role of protein kinase C in geranylgeranylacetone-induced expression of heat-shock protein 72 and cardioprotection in the rat heart. J Mol Cell Cardiol 2003; 35: 785-794.
35. Shinohara T, Takahashi N, Ooie T, Hara M, Shigematsu S, Nakagawa M, et al. Phosphatidylinositol 3-kinase dependent activation of akt, an essential signal for hyperthermia-induced heat-shock protein 72, is attenuated in streptozotocin-induced diabetic heart. Diabetes 2006; 55: 1307-1315.
36. Taniguchi Y, Takahashi N, Fukui A, Nagano-Torigoe Y, Thuc LC, Teshima Y, et al. Candesartan restored cardiac Hsp72 expression and tolerance against reperfusion injury in hereditary insulin resistant rats. Cardiovasc Res 2011; 92: 439-448.
37. Takahashi N, Wakisaka O, Yoshimatsu H, Saikawa T. Induction of heat shock proteins prevents the arrhythmogenic substrate for atrial fibrillation. Int J Hyperthermia 2009; 25: 641-646.
38. Soliman EZ, Prineas RJ, Go AS, Xie D, Lash JP, Rahman M, et al. Chronic kidney disease and prevalent atrial fibrillation: The Chronic Renal Insufficiency Cohort (CRIC). Am Heart J 2010; 159: 1102-1107.
39. Watanabe H, Watanabe T, Sasaki S, Nagai K, Roden DM, Aizawa Y. Close bidirectional relationship between chronic kidney disease and atrial fibrillation: The Niigata Preventive Medicine study. Am Heart J 2009; 158: 629-636.
40. Horio T, Iwashima Y, Kamide K, Tokudome T, Yoshihara F, Nakamura S, et al. Chronic kidney disease as an independent risk factor for new-onset atrial fibrillation in hypertensive patients. J Hypertens 2010; 28: 1738-1744.
41. Baber U, Howard VJ, Halperin JL, Soliman EZ, Zhang X, McClellan W, et al. Association of chronic kidney disease with atrial fibrillation among adults in the united states: Reasons for Geographic And Racial Differences in Stroke (REGARDS) study. Circ Arrhythm Electrophysiol 2011; 4: 26-32.
42. Campese VM. Neurogenic factors and hypertension in chronic renal failure. J Nephrol 1997; 10: 184-187.
43. Vaziri ND, Oveisi F, Ding Y. Role of increased oxygen free radical activity in the pathogenesis of uremic hypertension. Kidney Int 1998; 53: 1748-1754.
44. Vaziri ND, Dicus M, Ho ND, Boroujerdi-Rad L, Sindhu RK. Oxidative stress and dysregulation of superoxide dismutase and NADPH oxidase in renal insufficiency. Kidney Int 2003; 63: 179-185.
45. Elkareh J, Kennedy DJ, Yashaswi B, Vetteth S, Shidyak A, Kim EG, et al. Marinobufagenin stimulates fibroblast collagen production and causes fibrosis in experimental uremic cardiomyopathy. Hypertension 2007; 49: 215-224.
46. Bai Y, Sigala W, Adams GR, Vaziri ND. Effect of exercise on cardiac tissue oxidative and inflammatory mediators in chronic kidney disease. Am J Nephrol 2009; 29: 213-221.
47. Kim YM, Kattach H, Ratnatunga C, Pillai R, Channon KM, Casadei B. Association of atrial nicotinamide adenine dinucleotide phosphate oxidase activity with the development of atrial fibrillation after cardiac surgery. J Am Coll Cardiol 2008; 51: 68-74.
48. Kim YM, Guzik TJ, Zhang YH, Zhang MH, Kattach H, Ratnatunga C, et al. A myocardial Nox2 containing NAD(P)H oxidase contributes to oxidative stress in human atrial fibrillation. Circ Res 2005; 97: 629-636.
49. Bendall JK, Cave AC, Heymes C, Gall N, Shah AM. Pivotal role of a gp91(phox)-containing NADPH oxidase in angiotensin ii-induced cardiac hypertrophy in mice. Circulation 2002; 105: 293-296.
50. Ago T, Kuroda J, Pain J, Fu C, Li H, Sadoshima J. Upregulation of Nox4 by hypertrophic stimuli promotes apoptosis and mitochondrial dysfunction in cardiac myocytes. Circ Res 2010; 106: 1253-1264.
51. Kuroda J, Ago T, Matsushima S, Zhai P, Schneider MD, Sadoshima J. NADPH oxidase 4 (nox4) is a major source of oxidative stress in the failing heart. Proc Natl Acad Sci USA 2010; 107: 15565-15570.
52. Bataller R, Schwabe RF, Choi YH, Yang L, Paik YH, Lindquist J, et al. NADPH oxidase signal transduces angiotensin II in hepatic stellate cells and is critical in hepatic fibrosis. J Clin Invest 2003; 112: 1383-1394.
53. Del Rio D, Stewart AJ, Pellegrini N. A review of recent studies on malondialdehyde as toxic molecule and biological marker of oxidative stress. Nutr Metab Cardiovasc Dis 2005; 15: 316-328.
54. Husain K, Ferder L, Mizobuchi M, Finch J, Slatopolsky E. Combination therapy with paricalcitol and enalapril ameliorates cardiac oxidative injury in uremic rats. Am J Nephrol 2009; 29: 465-472.
55. Leftheriotis DI, Fountoulaki KT, Flevari PG, Parissis JT, Panou FK, Andreadou IT, et al. The predictive value of inflammatory and oxidative markers following the successful cardioversion of persistent lone atrial fibrillation. Int J Cardiol 2009; 135: 361-369.
56. Masuda T, Iwashita Y, Hagiwara S, Ohta M, Inomata M, Noguchi T, et al. Dihydrolipoyl histidinate zinc complex, a new antioxidant, attenuates hepatic ischemia-reperfusion injury in rats. J Gastroenterol Hepatol 2011; 26: 1652-1658.
57. Hagiwara S, Teshima Y, Takahashi N, Koga H, Saikawa T, Noguchi T. New lipoic acid derivative drug sodium zinc dihydrolipoylhistidinate prevents cardiac dysfunction in an isolated perfused rat heart model. Crit Care Med 2011; 39: 506-511.